• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Qlucore

0.30 SEK+13.16 %10.7. klo 18.29
Less than 1K followers

QCORE

First North Stockholm

IT Services

Technology

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+13.16 %
-25.31 %
-26.41 %
-38.82 %
-39.56 %
-10.21 %
-93.49 %
-
-98.92 %

Qlucore develops AI-based software for use in the healthcare sector. The company's precision medicine solutions transform genetic data into decision-making data to create the right treatment for patients. The company's first diagnostic test – for blood cancer in children – has been approved and CE-marked. The company also has tests for lung cancer under development, and is developing the Qlucore Omics Explorer analysis software.

Read more
Market cap
12.91M SEK
Turnover
29.77K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
9.9.
2026

Interim report Q1'27

9.9.
2026

General meeting '26

26.11.
2026

Interim report Q2'27

Press release23.06.2026 klo 20.20

Qlucore Receives EUR 0.5 Million EU Payment

Qlucore
Press release17.06.2026 klo 21.30

Qlucore Receives Approval for EUR 0.5 Million EU Payment

Qlucore
Regulatory press release28.05.2026 klo 09.30

Year-end-report 1 May 2025 - 30 April 2026

Qlucore

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release20.04.2026 klo 15.00

Qlucore Launches AI-based test for Bladder Cancer

Qlucore
Press release13.04.2026 klo 11.30

Qlucore Launches AI-based test for Acute Myeloid Leukemia

Qlucore
Regulatory press release26.02.2026 klo 09.30

Interim report 1 May 2025 - 31 January 2026

Qlucore
Press release23.02.2026 klo 18.10

Invitation to presentation including Q&A session of Qlucore’s interim report for the period 1 May 2025 – 31 January 2026

Qlucore
Press release18.12.2025 klo 15.00

New version of Qlucore Omics Explorer with enhanced support for in-depth proteomics analysis

Qlucore
Regulatory press release27.11.2025 klo 09.30

Interim report 1 May - 31 October 2025

Qlucore
Regulatory press release27.11.2025 klo 09.20

Disposal of intangible assets

Qlucore
Press release25.11.2025 klo 12.00

Invitation to presentation including Q&A session of Qlucore’s interim report for the period 1 May – 31 October 2025

Qlucore
Regulatory press release28.10.2025 klo 10.30

Qlucore terminates liquidity guarantee agreement

Qlucore
Regulatory press release23.10.2025 klo 13.30

Bulletin from the annual general meeting of Qlucore AB (publ)

Qlucore
Regulatory press release24.09.2025 klo 19.30

Interim report 1 May - 31 July 2025

Qlucore
Press release24.09.2025 klo 11.00

Invitation to presentation including Q&A session of Qlucore’s interim report for the period 1 May – 31 July 2025

Qlucore
Regulatory press release23.09.2025 klo 18.30

NOTICE OF ANNUAL GENERAL MEETING OF QLUCORE AB (publ)

Qlucore
Regulatory press release08.09.2025 klo 22.00

Last day of trading in BTA in Qlucore – conversion of BTA into shares

Qlucore
Regulatory press release04.09.2025 klo 21.00

Qlucore carries out a directed share issue to guarantors

Qlucore
Regulatory press release01.09.2025 klo 20.00

Qlucore announces outcome of rights issue

Qlucore
Regulatory press release22.08.2025 klo 10.00

Qlucore secures guarantee commitments as well as additional subscription commitments ahead of rights issue

Qlucore